Primary lactase deficiency (PLD) is a common inherited condition caused by a reduced activity of lactase. Two single-nucleotide polymorphisms C/T -13910 and G/A -22018 upstream of the lactase gene are associated with lactase nonpersistence. In celiac disease (CD) patients, lactose intolerance could be due to secondary lactase deficiency and to PLD. The aim of this study were to evaluate the association of PLD and CD using genetic test, and to define the prevalence of PLD in celiac subjects compared with a control population. A total of 188 controls and 92 biopsy-proven CD patients were included in the study. More than 70% of all subjects were found homozygous for the polymorphisms. Differences in the prevalence of PLD were not found between CD patients and controls.In conclusions, the hereditary lactase deficiency is frequent in Italian CD children as in control population.
INTRODUCTION
Lactose intolerance is a clinical syndrome, including abdominal pain, diarrhea, nausea, flatulence and/or bloating, after the ingestion of lactose or lactose-containing food substances. 1 Primary lactase deficiency (PLD) is due to relative or absolute absence of lactase that develops in childhood at various ages and is the most common cause of lactose malabsorption and lactose intolerance. 1 PLD is a common inherited condition caused by a reduced lactase activity, 2 encoded by two genes located on the long arm of chromosome 2:
3 the C/T -13910 and G/A -22018 4-6 (see Table 1 for details). Secondary lactase deficiency instead results from small bowel injury. It can present at any age although it is common in infancy. 1 In celiac disease (CD), clinical signs of lactose intolerance have been frequently reported in patients considered unresponsive to gluten-free diet, 7 making them candidates for specific management with a lactose-restriction diet. In CD patients, the lactose intolerance could be due to secondary lactase deficiency and to PLD especially in the population where there is a high risk for this genetic defect.
The aim of this study was to evaluate the association of PLD and CD by comparing the prevalence of PLD in celiac subjects and in a control population.
MATERIALS AND METHODS
Setting of the study was the Hepatology, Gastroenterology and Nutrition Unit of the Pediatric Hospital Bambino Gesù in Rome.
Between June and December 2010, all consecutive CD patients with a biopsy-proven diagnosis 8 were enrolled. Control subjects were recruited at the Department of Surgery, to which they had been referred for minor surgical procedures.
Inclusion criteria for CD patients and controls were as follows:
Negative antitissue transglutaminase of immunoglobulin (Ig) A class or, in subjects with IgA deficiency, negative antitissue transglutaminase of IgG class. No symptoms, in the clinical history, suggestive for lactose intolerance.
A written informed consent to the study was obtained from the patients' families; the Ethical Committee of our hospital approved this study.
Methods tTG, IgA and human leukocyte antigen. An enzyme-linked immunosorbent assay kit (Eu-tTG, Eurospital, Italy) was used to measure tTG (normal value o4 IU/ml; positive value 47 IU/ml and borderline value 4-7 IU/ml). Patients' total serum IgA was determined by means of a Boeringer Mannheim Hitachy 912 Analyzer, with Tina-quant reagents (Roche Diagnostics GmbH, Mannheim, Germany). To determine human leukocyte antigen DQ2-DQ8, type Eu-DQ (Eurospital) was used as indicated by the manufacturer.
Lactose genetics test. The test used, Sugar Intolerance StripAssay (Nuclear Laser Medicine, Settala, Italy), identifies two mutations located upstream of the LCT gene.
Statistical analysis. Statistical data were generated with the GraphPad Prism version 3.00 for Windows software (GraphPad Software, San Diego, CA, USA).
To ascertain whether possible differences in PLD between patients and controls could be clinically meaningful, we had previously estimated the required sample size by calculating the a and b probabilities of type I and Lactase nonpersistence (%) Lactase persistence (%)
Hepatology, Gastroenterology and Nutrition Unit, Pediatric Hospital Bambino Gesu' Rome, Italy and type II errors, respectively. By assuming that the expected prevalence of PLD was 50-70% in our population (CD patients and controls), accepting a power of 0.80 and a 0.05 two-sided type I error, we calculated that at least 70 patients and 140 controls should be enrolled. The w 2 test and the t-test were used to compare differences in the categorical variables and in the continuous variables, respectively, between the two groups. For all statistical analyses a two-tailed P-value of 0.05 was considered significant.
RESULTS
At the end of the study period, 188 controls and 92 CD patients were included. More than 70% of all subjects were found positive for the C/C polymorphism at C/T -13910 and for the G/G polymorphism at G/A -22018 , without significant differences between CD patients and controls (see Table 2 for details). DISCUSSION PLD and CD are two highly prevalent genetic disorders involving the small bowel mucosa. The potential consequence of the coexistence of CD and PLD is that the symptoms of the lactase deficiency associated with CD might be mistaken for poor adherence to GFD. Conversely, the abstinence from milk could cause further problems for a celiac patient already adversely affected by diet. This is the first report about the association between PLD and CD. The main results were the following: (a) the prevalence of PLD in Italian children affected by CD is not different from that observed in control subjects; (b) both CD children and controls remain asymptomatic for lactose intolerance despite of the high prevalence of the two genetic polymorphisms.
Approximately 70% of the world's population has a PLD. 9 The prevalence of PLD varies according to the ethnicity ranging from 2% in northern European people to 80% in Hispanic, black and Ashkenazi Jewish people. 1 Our study provides further data on the prevalence of the PLD in the Italian paediatric population: 77.5% of our population has T4C 13910 polymorphism, accordingly to a previous Italian study from a Northern Region. 10 However, the same high prevalence was found in CD patients. This additional pathogenic factor should be considered in the follow-up of CD with negative serology and in the evaluation of gastrointestinal symptoms that CD patients can develop. Our study suggests that in the populations at high risk of PLD, this genetic defect should be considered during the course of CD. 1 Nevertheless, a positive genetic test for lactase nonpersistence indicates that lactase activity will decline over time. It is possible that the activity of lactase deficiency is compensated by the action of bacterial flora, which is expressed through the metabolism of bacteria of the genus Lactobacillus, which are able to metabolize lactose. This activity could mask for long periods the lactase deficiency, as confirmed by the late onset of symptoms at adolescence and at adulthood in the majority of lactase-deficient individuals. 1 The genetic test does not indicate the actual presence of lactose malabsorption for which the lactose breath test is required. 1 In conclusion, the genetic markers of hypolactasia are equally represented in CD children and in controls. As the onset of lactose intolerance symptoms typically is progressive over many years, they should be monitored over time in the follow-up of CD patients with persistent digestive complaints and negative serology. 
